|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 38/00 | (2006.01) |
| A61P 29/00 | (2006.01) |
| (11) | Number of the document | 2269622 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10162989.7 |
| Date of filing the European patent application | 2006-06-29 | |
| (97) | Date of publication of the European application | 2011-01-05 |
| (45) | Date of publication and mention of the grant of the patent | 2013-12-25 |
| (46) | Date of publication of the claims translation | 2014-06-25 |
| (30) | Number | Date | Country code |
| 696173 P | 2005-07-01 | US |
| (72) |
Löfberg, Robert, SE
von Stein, Oliver, SE
Zargari, Arezou, SE
|
| (73) |
Index Pharmaceuticals AB,
Scheeles väg 2, 171 77 Stockholm,
SE
|
| (74) |
Otilija KLIMAITIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | CpG oligonukleotidai naudojami nuo steroidų priklausomų pacientų steroidų aktyvumo pagerinimui |
| CpG oligonucleotides used for enhancing steroid activity in a steroid dependent patient |
| Payment date | Validity (years) | Amount | |
| 2021-06-15 | 16 | 347.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2022-06-29 |